与单独使用多西他赛相比,177Lu-PSMA-617和多西他赛的序贯使用改善了新发、高瘤负荷mHSPC的临床结局,且并未增加毒性。研究结果进一步支持177Lu-PSMA-617治疗mHSPC患者。 ▌参考文献: Azad A. A., Bressel M., Tan, H., et al. LBA...
针对 177Lu-PSMA-617 这一靶向治疗手段在前列腺癌中的精准治疗应用也成为了本次会议的热门议题之一,其相关研究结果对于患者筛选及个体化精准治疗有着重要指导意义。 对此,丁香园特邀四川大学华西医院魏强教授、上海市第一人民医院韩邦旻教授...
1. Sartor O, de Bono J, Chi KN, et al: Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385:1091-1103, 2021 2. Garje R, Rumble RB, Parikh RA. Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASC...
1. Sartor O, de Bono J, Chi KN, et al: Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385:1091-1103, 2021 2. Garje R, Rumble RB, Parikh RA. Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASC...
与单独使用多西他赛相比,177Lu-PSMA-617和多西他赛的序贯使用改善了新发、高瘤负荷mHSPC的临床结局,且并未增加毒性。研究结果进一步支持177Lu-PSMA-617治疗mHSPC患者。 ▌参考文献: Azad A.A.,Bressel M.,Tan,H.,et al.LBA66 UpFrontPSMA:A randomised phase II study of sequential 177Lu-PSMA-617 and docet...
This phase 1 dose-escalation and dose-expansion study is designed to evaluate the safety and tolerability of olaparib in combination with 177Lutetium-Prostate Specific Membrane Antigen (177 Lu-PSMA) in patients with metastatic castration resistant prostate cancer (mC...
LuPSMA is given at the standard dose of 7.4GBq every 6 weeks, and carboplatin is dosed every 3 weeks, with 6 weeks constituting 1 cycle. In phase 1a, a 3+3 design is used with 3 planned dose levels of carboplatin (DL1 – AUC2; DL2 – AUC3: DL3 – AUC4); the dose-limiting ...
Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901). LBA84 Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II ...
The hypothesis of this phase I study is that combining EBRT and ADT (in accordance to current standard of care) with one cycle of systemic [177Lu]Lu-PSMA-617 delivered in week two of EBRT, in treatment naïve patients with PSMA-positive N1M0 prostate cancer will not induce significant add...
李永红教授:177Lu标记的以PSMA为靶点的放射性配体疗法是近年来用于晚期前列腺癌患者治疗的全新方案,国内外多个指南共识已经将177Lu-PSMA-617写入晚期前列腺癌治疗的推荐用药,但国内目前还没有规范性指导用药的相关文章发表。由中国抗癌协会肿瘤核医学专业委员会和中国医师协会核医学医师分会发起,多名来自不同省市的专家执...